

The use of delamanid in the treatment of multidrug-resistant tuberculosis

Interim policy guidance



**World Health
Organization**

The use of delamanid in the treatment of multidrug-resistant tuberculosis

Interim policy guidance



**World Health
Organization**

WHO/HTM/TB2014.23

© **World Health Organization 2014**

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in France

Design by Inis Communication – www.iniscommunication.com



Contents

| | |
|---|-------------|
| Abbreviations | .iii |
| Acknowledgements | v |
| Executive summary | 1 |
| 1. Background | 10 |
| 2. Guideline purpose and target audience | 12 |
| 2.1. Purpose | 12 |
| 2.2 Target audience | 12 |
| 3. Guideline development process | 13 |
| 3.1 Expert Group meeting | 13 |
| 3.2 Management of conflicts of interest. | 13 |
| 3.3 Review of evidence | 14 |
| 3.4 Decision-making during the Expert Group meeting | 16 |
| 3.5 External peer review | 17 |
| 3.6 Financial support | 17 |
| 4. Evidence base for policy formulation | 18 |
| 4.1 Evidence for the efficacy of delamanid in the treatment of MDR-TB | 20 |
| 4.2 Evidence for the safety of delamanid in the treatment of MDR-TB | 24 |
| 4.3 Cost-effectiveness. | 26 |
| 5. Expert Group recommendations | 27 |
| 5.1 Summary of evidence for the recommendation | 27 |
| 5.2 Expert Group recommendations | 30 |
| 6. WHO interim policy recommendations | 32 |
| 7. Further research | 37 |
| 8. Dissemination and implementation | 38 |

| | |
|--|-----------|
| References | 48 |
| Annex 1: List of WHO guideline Steering Group members | 49 |
| Annex 2: List of Expert Group members | 50 |
| Annex 3: Expert Group meeting on interim guidance for the use of delamanid in the treatment of multidrug-resistant tuberculosis | 52 |
| Annex 4: Declarations of interest | 56 |
| Annex 5: GRADE glossary | 61 |
| Annex 6: List of Expert Review Panel members | 65 |

List of Figures

| | |
|---|----|
| Figure 1: Design of delamanid Trial 204, Trial 208 and Study 116 | 19 |
| Figure 2: Proportion of patients with sputum-culture conversion by Day 57 | 21 |

List of Tables

| | |
|---|----|
| Table 1: Favourable treatment outcome and mortality at 24 months for MDR-TB patients treated with delamanid | 23 |
| Table 2: Outcome at 24 months for patients consenting to participate in Study 116 who were treated with delamanid 100mg BD or 200mg BD + OBR for two, six or eight months or with OBR alone, using WHO treatment outcome categories (N=421) | 23 |
| Table 3: Incidence of adverse events (occurring in 10% of patients in either delamanid group and with greater frequency than in the placebo group)* | 25 |
| Table 4: The GRADE evidence profile summary | 39 |
| Table 5: The GRADE evidence to recommendation. | 42 |



Abbreviations

| | |
|--------|--|
| AIDS | acquired immunodeficiency syndrome |
| ART | antiretroviral therapy |
| BD | twice daily |
| CEA | cost effectiveness analysis |
| CEM | cohort event monitoring |
| CI | confidence interval |
| CHMP | Committee for Medicinal Products for Human Use |
| DDI | drug drug interaction |
| DoI | declaration of interests |
| DOT | directly observed treatment |
| DOTS | basic package that underpins the WHO Stop TB Strategy |
| DST | drug-susceptibility testing |
| ECG | electrocardiogram |
| EG | Expert Group |
| ERP | External Review Panel |
| EMA | European Medicines Agency |
| GTB | WHO Global TB Programme |
| GRADE | Grading of Recommendations, Assessment, Development and Evaluation |
| GRC | Guidelines Review Committee |
| HIV | human immunodeficiency virus |
| ITT | intention to treat |
| MDR-TB | multidrug-resistant tuberculosis |
| MIC | minimal inhibitory concentration |
| MGIT | mycobacteria growth indicator tube liquid culture system |
| MITT | modified intention to treat |
| NTP | national tuberculosis programme |
| OBR | optimized background regimen |
| PICO | population, intervention, comparator, outcome |
| PLHIV | people living with HIV |
| PMDT | programmatic management of drug-resistant tuberculosis |

| | |
|--------|---|
| QT | the interval from the beginning of the QRS complex to the end of the T wave on an electrocardiogram |
| QTcF | QT interval corrected for heart rate according to the Fridericia method |
| RCT | randomized controlled trial |
| RR | relative risk |
| SAE | severe adverse event |
| SCC | sputum culture conversion |
| SRA | stringent regulatory authority |
| SSM | sputum-smear microscopy |
| TB | tuberculosis |
| TEAE | treatment-emergent adverse effects |
| USAID | United States Agency for International Development |
| XDR-TB | extensively-drug resistant tuberculosis |
| WHO | World Health Organization |

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27824

